文献速递妇科

POLE突变子宫内膜样子宫内膜癌患者的临床结局

Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer.
PubMed 文献 · Gynecol Oncol · 2019-11-19

该研究对2014至2018年间测序的451例子宫内膜样子宫内膜癌(EEC)进行回顾性分析,其中23例(5%)携带POLE核酸外切酶域突变(EDM)。中位随访30个月后,4/23(17%)出现复发,另1例晚期患者治疗后进展。作者认为POLE EDM EEC总体预后良好,但本真实世界队列中仍观察到初诊转移及早期病例复发,将POLE EDM纳入辅助治疗决策前需进一步研究。

要点

  • 451例EEC中23例(5%)携带POLE EDM,其中19例(83%)为I/II期,4例(17%)为III/IV期。
  • 中位随访30个月,4/23(17%)复发:3例为初始3级I期,1例为1级III期。
  • 5例(22%)存在DNA错配修复蛋白表达缺失,均非Lynch综合征所致。

核心结论

  • 作者认为POLE EDM的EEC患者预后良好,但本真实世界队列中观察到初诊转移及初始局限于子宫病例的复发。
  • 作者提出将POLE EDM纳入辅助治疗决策前需进一步研究。

研究设计与样本

  • 对2014至2018年接受测序的子宫内膜样子宫内膜癌(EEC)进行临床队列分析。
  • 患者同意接受肿瘤-正常组织410-468个癌症相关基因的大规模平行测序。
  • 共451例EEC完成测序,其中23例携带体细胞POLE核酸外切酶域突变(EDM),包括20例原发肿瘤和3例复发肿瘤。

主要发现

  • 23例POLE EDM患者中,19例(83%)为I/II期,4例(17%)为III/IV期;13例(57%)为FIGO 1/2级,10例(43%)为3级。
  • 所有患者均接受手术治疗,17例(89%)接受辅助治疗。
  • 5例(22%)存在DNA错配修复蛋白表达缺失,均非Lynch综合征所致。
  • 中位随访30个月后,4/23(17%)出现复发:3例为初始3级I期,1例为1级III期;另1例2级IV期EEC患者治疗后出现疾病进展。

关键数值与推荐

  • MSIsensor评分对21份样本可得出结论:19例为微卫星稳定,2例为微卫星高度不稳定。

临床怎么用

  • 作者认为将POLE EDM状态纳入辅助治疗决策前需进一步研究。

局限性

  • 作者提出将POLE EDM纳入辅助治疗决策前需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Assess outcomes of a clinical cohort of patients with endometrioid endometrial cancer (EEC) harboring somatic POLE exonuclease domain mutations (EDMs). METHODS: Patients were consented to a protocol of tumor-normal massively parallel sequencing of 410-468 cancer related genes. EECs subjected to sequencing from 2014 to 2018 were reviewed. Tumors with somatic POLE EDMs were identified. EECs were assessed for microsatellite instability (MSI) using MSIsensor and immunohistochemical analysis for mismatch repair (MMR) proteins. RESULTS: Of the 451 EECs sequenced, 23 had a POLE EDM (5%): 20 primary and 3 recurrent tumors sequenced. Nineteen cases (83%) were stage I/II and 4 (17%) were stages III/IV. Thirteen EECs (57%) were of FIGO grades 1/2, 10 (43%) grade 3. All patients were treated with surgery and 17 (89%) received adjuvant therapy. Five (22%) demonstrated loss of DNA MMR protein expression, none were due to Lynch syndrome. MSIsensor scores were conclusive for 21 samples: 19 were microsatellite stable and 2 MSI-high. After median follow-up of 30 months, 4/23 (17%) developed recurrences: 3 with initial grade 3 stage I and 1 with grade 1 stage III disease. One patient with grade 2 stage IV EEC had progressive disease after treatment. CONCLUSIONS: Patients with POLE EDM EEC have been shown to have a favorable prognosis. In this real-world cohort of patients, de novo metastatic disease and recurrences in initially uterine-confined cases were observed. Further research is warranted before incorporating the presence of POLE EDM into decision-making regarding adjuvant therapy.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Stasenko M, Tunnage I, Ashley CW, et al. Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer. Gynecol Oncol. 2019. PMID: 31757464. doi:10.1016/j.ygyno.2019.10.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。